



CORRES. AND MAIL

BOX AF

JAB 828

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 12021

Applicant : Cornelius G. M. Janssen et al.
Serial No.: 07/932,142 Art Unit: 1202
Filed : August 19, 1992 Examiner: M. Berch
For : NOVEL 3-PIPERIDINYL-1,2-BENZISOXAZOLES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on April 7, 1993
(Date of Deposit)

RECEIVED
APR 15 1993
GROUP 1200

Charles J. Metz
Name of Registered Representative

Charles J. Metz
(Signature)

April 7, 1993
(Date of Signature)

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

RESPONSE UNDER 37 CFR 1.116

This letter is in response to the Office Action of March 17, 1993.

Enclosed herewith is a new Terminal Disclaimer in which the Assignee, Janssen Pharmaceutica N.V., disclaims the terminal part of any patent granted on this application which would extend beyond the expiration date of U.S. Patent No. 5,158,952. The new Terminal Disclaimer includes the certification required by 37 CFR 3.73(b).

Also enclosed is the \$110.00 fee for filing the Terminal Disclaimer.

It is respectfully submitted that the rejection of Claims 20-25 under the judicially created doctrine of obviousness-type double patenting over Claims 1-3 of U.S. Patent No. 5,158,952 has been overcome by the present Terminal Disclaimer, and that this application is now in condition for allowance. Early favorable action is respectfully requested.

Respectfully submitted,



Charles J. Metz
Attorney for Applicants
Registration #20,359

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933

(908) 524-2814

April 7, 1993